DGAP-News: BioCrea GmbH: BioCrea to Present at BioTrinity 2014 on 13 May 2014

DGAP-News: BioCrea GmbH / Key word(s): Miscellaneous
BioCrea GmbH: BioCrea to Present at BioTrinity 2014 on 13 May 2014

09.05.2014 / 10:00

---------------------------------------------------------------------

Radebeul, Germany, May 09, 2014 - BioCrea GmbH (BioCrea), the
first-in-class CNS drug discovery specialist, today announced that Chief
Executive Officer, Dr. Tom Kronbach, will present at BioTrinity 2014,
Europe's leading Biopartnering and Investment Conference, to be held on
12-14 May in London.

Tom Kronbach will be presenting on May 13, 2014 at 13:50 BST in the Alsace
Room, Mezzanine Floor, Novotel London West, UK.

"This is a wonderful opportunity for BioCrea to present its lead programs
and novel discovery platforms to over 30 major pharmaceutical companies,"
said Dr. Tom Kronbach, CEO of BioCrea. "In partnering terms, we will talk
about our two unique proprietary small molecule programs: Long-term acting
GABAA positive allosteric modulators (LT GABAA PAMs) to treat epilepsy plus
autism; and NMDA receptor 2B (NR2B) negative allosteric modulators (NAMs)
to treat depression. Both programs are expected to reach the IND-enabling
study phase later this year."

Founded and produced by OBN, BioTrinity has become the "must attend" life
sciences conference for emerging European companies, investors and
partners. The conference is now in its eighth year. BioTrinity has grown
rapidly over recent years, and is now located in London to accommodate
increased interest. More than 1000 senior executives and decision makers
from emerging and established companies across the life sciences sector and
investment firms are expected to meet one-on-one, attend panel discussions
and workshops, or browse the company showcases, seeking out their next
deals.

About BioCrea

BioCrea, the Radebeul-based first-in-class drug discovery specialist
validated through pharma partnerships, has established a number of programs
in neurological and psychotic disorders. Its proven expertise is based on
proprietary compound libraries, medicinal chemistry, molecular modeling and
advanced screening technologies. BioCrea uses this expertise in an
innovative multi-parameter optimization approach to generate and deliver
CNS drug candidates that offer significant potential for greater efficacy
and tolerability. Moreover, the patient-derived stem cell (iPSC) platform
has been successfully developed to discover high value preclinical drug
candidates for neurodegenerative diseases such as amyotrophic lateral
sclerosis (ALS, Lou Gehrig's disease). BioCrea was awarded Top Innovator
status of the "Top 100" Most Innovative Companies in Germany 2012 by
compamedia GmbH. For more information, please visit www.biocrea.com.

About OBN

OBN is the membership organisation supporting and bringing together the
UK's emerging life sciences companies, corporate partners and investors.
Our Membership of around 300 companies, spread across the Golden Triangle
(formed by the cities of Oxford, Cambridge and London) and beyond to
Nottingham, Manchester and Scotland, benefits from tailored networking and
partnering events, group purchasing, advice and advocacy.
 
OBN founded and produces BioTrinity, Europe's largest annual Biopartnering
and Investment Conference for emerging companies. Attracting around 1,000
senior delegates from Europe, Asia and North America, BioTrinity generates
more R&D-company-to-investor interactions than any similar European event.
For further information on OBN and its activities, visit: www.obn.org.uk.

Contact

Dr. Tom Kronbach
CEO, BioCrea GmbH
Tel.: +49 351 / 4043 3332
Fax: +49 351 / 4043 3216
tom.kronbach@biocrea.com


End of Corporate News

---------------------------------------------------------------------

09.05.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


267460 09.05.2014